Mucinous colorectal adenocarcinoma: Clinicopathological features, molecular profiling, and therapeutic challenges

Mucinous colorectal adenocarcinoma (MAC) accounts for approximately 10% of all colorectal cancers and is defined by the presence of extracellular mucin in more than 50% of the tumour volume. The prognosis of MAC compared with non-mucinous colorectal adenocarcinoma remains debated, with reported outcomes influenced by tumour stage, location and molecular characteristics. MAC is frequently diagnosed at a more advanced stage, exhibits increased lymph node involvement and a greater tendency towards peritoneal metastases, and has been associated with reduced response to neoadjuvant chemoradiotherapy, particularly in rectal cancer. Moreover, mucinous differentiation is associated with distinct clinicopathological, molecular and epigenetic features, including higher frequencies of microsatellite instability (MSI), CpG island methylator phenotype (CIMP) and BRAF mutations. Nevertheless, current clinical guidelines do not provide separate treatment recommendations for this histological subtype, and management remains guided by disease stage, resectability and established molecular biomarkers. In this review, we explore the current literature to summarise the epidemiology and prognosis, distinct clinicopathological features, molecular characteristics, diagnostic techniques and management of MAC, including recent advances in surgical treatment, targeted molecular therapy and immunotherapy. As our understanding of the molecular biology of mucinous colorectal adenocarcinoma continues to evolve, advances in molecular profiling may facilitate more precise risk stratification and the development of targeted and personalised treatment approaches.

Authors

Institutions

Publication Details

Journal
Surgical Oncology
Published
2026-11-18
DOI
https://doi.org/10.1016/j.suronc.2026.102612
Primary Topic
Colorectal Cancer Treatments and Studies
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Mucinous colorectal adenocarcinoma: Clinicopathological features, molecular profiling, and therapeutic challenges

Athina Anagnou, Theodora Pissanou, Μιλτιάδης Καστανάκης, Chrysanthi Simou et al.
1 links
Surgical Oncology
Colorectal Cancer Treatments and Studies
article

Mucinous colorectal adenocarcinoma: Clinicopathological features, molecular profiling, and therapeutic challenges

Athina Anagnou, Theodora Pissanou, Μιλτιάδης Καστανάκης, Chrysanthi Simou, Evangelos Lolis, Giorgos Tsismenakis
article en

Abstract

Mucinous colorectal adenocarcinoma (MAC) accounts for approximately 10% of all colorectal cancers and is defined by the presence of extracellular mucin in more than 50% of the tumour volume. The prognosis of MAC compared with non-mucinous colorectal adenocarcinoma remains debated, with reported outcomes influenced by tumour stage, location and molecular characteristics. MAC is frequently diagnosed at a more advanced stage, exhibits increased lymph node involvement and a greater tendency towards peritoneal metastases, and has been associated with reduced response to neoadjuvant chemoradiotherapy, particularly in rectal cancer. Moreover, mucinous differentiation is associated with distinct clinicopathological, molecular and epigenetic features, including higher frequencies of microsatellite instability (MSI), CpG island methylator phenotype (CIMP) and BRAF mutations. Nevertheless, current clinical guidelines do not provide separate treatment recommendations for this histological subtype, and management remains guided by disease stage, resectability and established molecular biomarkers. In this review, we explore the current literature to summarise the epidemiology and prognosis, distinct clinicopathological features, molecular characteristics, diagnostic techniques and management of MAC, including recent advances in surgical treatment, targeted molecular therapy and immunotherapy. As our understanding of the molecular biology of mucinous colorectal adenocarcinoma continues to evolve, advances in molecular profiling may facilitate more precise risk stratification and the development of targeted and personalised treatment approaches.

Surgical OncologyVol. 70
Royal Free London NHS Foundation Trust (GB), The Royal Free Hospital (GB), Chania General Hospital ”St. George” (GR), University Hospital of Ioannina (GR)
Good health and well-being
Colorectal Cancer Treatments and Studies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon